 |
2 Diseases |  |
27 Trials |
|
27 Trials |  |
1089 News |  |
| «12...45678910111213141516» |
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Association of baseline cardiac troponin T with cardiovascular death, HF hospitalization in HFrEF & vericiguat’s benefit in VICTORIA was examined by @ChrisDefilippi and @coconnormd #ACC21 (Twitter) - May 16, 2021
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: #VICTORIAtrial showed that vericiguat was safe and well-tolerated--but in which #heartfailure cases should it be used? At #ACC21, @texhern provides an overview of when vericiguat may be a good #HF treatment option. (Twitter) - May 15, 2021
- |||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Confused about new & emerging breakthroughs in #HeartFailure #HFrEF SGLT2i? Vericiguat? Omecamtiv? Check out upcoming #ACC21 #ACCHFT session w/ insights from @texhern @jteerlinkmd & more! Starts at 2 PM @DrNasrien @AKBhatiaMD #ACCFIT #ACCEarlyCareer (Twitter) - May 15, 2021
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: What’s new in chronic #heartfailure 📍don’t be paralyzed by #CKD - renal outcomes improve w/ #HF therapies 📍consider add-on therapies - ivabridine, vericiguat, hydralazine/nitrates 📍continue therapy after remission 📍advocate for affordable access to Tx 2/3 @JonathanDavisHF (Twitter) - May 11, 2021
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases. (Pubmed Central) - May 11, 2021
Tadalafil, sildenafil, and cinaguat were evaluated for the treatment of PAH, whereas vericiguat was investigated in the treatment of HF patients with reduced ejection fraction. Furthermore, supplementation with hydrogen sulfide, tetrahydrobiopterin, and nitrite/nitrate has shown beneficial effects at the vascular level.
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Agreed! This is only going to get worse as vericiguat and omecamtiv hit the market. Need to find a way to help patients with significant financial trade offs! (Twitter) - May 10, 2021
- |||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Insightful discussion by @DktrV #hfupdate on evidence for & implementation of the recent innovations in @CanHFSociety @SCC_CCS Guidelines. “Foundational 4 (ARNI, BB, MRA, SGLT2i)” then address “residual risk” (consider ivadrabine, vericiguat) @ShelleyZieroth @AniqueDucharme (Twitter) - May 8, 2021
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Fantastic presentation by @JustinEzekowitz on #Vericiguat in #HF, #WHF. @CanHFSociety, #HFupdate, @HFSA (Twitter) - May 7, 2021
- Verquvo (vericiguat) / Bayer, Merck (MSD)
[VIRTUAL] What’s New in HFrEF: The Role of Vericiguat (Topic Essentials 1) - May 4, 2021 - Abstract #ACC2021ACC_9372;
Furthermore, supplementation with hydrogen sulfide, tetrahydrobiopterin, and nitrite/nitrate has shown beneficial effects at the vascular level. There is no abstract associated with this presentation.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
[VIRTUAL] What about vericiguat? () - May 1, 2021 - Abstract #HEARTFAILURE2021HEART_FAILURE_382;
- Verquvo (vericiguat) / Bayer, Merck (MSD)
[VIRTUAL] How to use the new drugs (vericiguat, SGLT2i, IV iron, etc). () - May 1, 2021 - Abstract #HEARTFAILURE2021HEART_FAILURE_361;
- Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
[VIRTUAL] Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis () - May 1, 2021 - Abstract #HEARTFAILURE2021HEART_FAILURE_145;
In a sensitivity leave one-out analysis, the comparative ordering of treatments was not substantially modified, but removing DAPA-HF, SUCRA scores of ARNI (85.8%) and ivabradine (73.4%) became higher than that of SGLT2i (64.4%). Conclusions The most recent medical therapies provide an additional benefit over NEUi in patients with HFrEF and CKD, which appears to be maximum with SGLT2i.
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Cost will be a big issue esp for newer non generics like ARNI, SGLT2 and now vericiguat (Twitter) - Apr 28, 2021
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
I’ve been kind of 🤷🏻♂️ about #vericiguat, but this data I just saw from @JustinEzekowitz @JACCJournals with a HR of 0.77 if NTProBNP <4000 makes me see it in a different light. Curious what others think @ATRIUMRx @accpcardprn https://t.co/2CYP48FWMi (Twitter) - Apr 21, 2021
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
☝️ cGMP in #HG focus on #Vericiguat impact on 🏥 in #HFrEF @DBelardoMD @JJheart_doc @DrNasrien @iamritu @MaasAngela @SABOURETCardio @drraviele @gbiondizoccai @Dr_Manito @IC_LaFe @lucreciamburgos @AndreasGevaert @KTamirisaMD @HFA_President @FH_Verbrugge https://t.co/1zkTlTtJUH (Twitter) - Apr 19, 2021
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Vericiguat (Verquvo) for heart failure. (Pubmed Central) - Apr 15, 2021
Conclusions The most recent medical therapies provide an additional benefit over NEUi in patients with HFrEF and CKD, which appears to be maximum with SGLT2i. No abstract available
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Review, Journal: Updates in pharmacotherapy of heart failure with reduced ejection fraction. (Pubmed Central) - Apr 15, 2021
Vericiguat is an oral guanylate cyclase stimulator that through the recent VICTORIA trial showed a 10% relative difference in death from cardiovascular cause or hospitalization for heart failure...The CANVAS and EMPA-REG OUTCOME trials showed the potential benefit of SGLT2 inhibitors on cardiovascular mortality, DECLARE-TIMI 58 trial showed that treatment with dapagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure to a greater extent in patients with reduced ejection fraction (EF)...Another rapidly expanding area of research in the realm of heart failure is precision medicine and its impact on the development, progression, and treatment of heart failure. The field of heart failure is dynamic and with the influx of data from recent and ongoing trials, newer therapies with morbidity and mortality benefits in HFrEF are now available, nonetheless, much work is still needed.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
[VIRTUAL] Budget IMPACT Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event in the United States () - Apr 12, 2021 - Abstract #ISPOR2021ISPOR_105;
P3
The field of heart failure is dynamic and with the influx of data from recent and ongoing trials, newer therapies with morbidity and mortality benefits in HFrEF are now available, nonetheless, much work is still needed. Adding vericiguat to commercial plan formulary was associated with limited budget impact, primarily driven by drug acquisition costs but partially offset by reduced cost of HFHs and CV deaths.
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: New treatments for systolic heart failure (Pubmed Central) - Mar 26, 2021
But since 2010, new molecules acting on complementary pathophysiological processes have been showing positive results. Recalling the recommended algorithm for optimizing the treatment of HF, we discuss in this article the mechanisms of action and the results of the latest clinical trials with SGLT2 inhibitors (gliflozines), vericiguat and percutaneous treatment of functional mitral regurgitation that will in the very short term modify the prescriptions of our HF patients.
- | valsartan / Generic mfg.
Journal: Comparison table: Some drugs for HFrEF. (Pubmed Central) - Mar 24, 2021
Recalling the recommended algorithm for optimizing the treatment of HF, we discuss in this article the mechanisms of action and the results of the latest clinical trials with SGLT2 inhibitors (gliflozines), vericiguat and percutaneous treatment of functional mitral regurgitation that will in the very short term modify the prescriptions of our HF patients. No abstract available
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Agree. And there is still room for the art of bedside medicine. Role for ivabridine, vericiguat, omecamptiv mecarbil to supplement patients who don’t tolerate or are not candidates for the “4 pillars” - also, novel device therapies barostim and CCM may play role. Phenogroup. Yes. (Twitter) - Mar 13, 2021
- | Verquvo (vericiguat) / Bayer, Merck (MSD)
Journal: Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply. (Pubmed Central) - Feb 26, 2021
No abstract available No abstract available
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Journal: Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. (Pubmed Central) - Feb 26, 2021
No abstract available No abstract available
- ||||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical: Can a flabby poorly contracting heart (HFrEF) be stiff, & relaxing poorly (diastolic dysfunction) Definitely.But what are best therapeutic options in these cases Will targeting therapy for poor contraction +diminished relaxation help SGLT2i + Ranolazine + BB + Vericiguat Any data (Twitter) - Feb 20, 2021
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
Clinical, Journal: Vericiguat in Heart Failure With Reduced Ejection Fraction With High Natriuretic Peptides: A Case of Too Little, Too Late? (Pubmed Central) - Feb 18, 2021
No abstract available No abstract available
- Verquvo (vericiguat) / Bayer, Merck (MSD)
[VIRTUAL] CORONARY ARTERY DISEASE AND CARDIOVASCULAR OUTCOMES IN HEART FAILURE: INSIGHTS FROM THE VERICIGUAT GLOBAL STUDY IN SUBJECTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_7293;
The effect of vericiguat was similar irrespective of CAD in this HF population. These data may assist in the planning of future trials.
- Verquvo (vericiguat) / Bayer, Merck (MSD)
[VIRTUAL] BASELINE CARDIAC TROPONIN T, CLINICAL OUTCOMES AND VERICIGUAT TREATMENT EFFECT IN HEART FAILURE WITH REDUCED EJECTION FRACTION STUDY: INSIGHTS FROM THE VICTORIA TRIAL (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_4217;
Baseline cTnT was significantly associated with CVD and HFH in VICTORIA and exhibits a spectrum of CVD risk associated with vericiguat treatment. cTnT appears important in identifying high-risk HFrEF and may influence treatment choices.
- Verquvo (vericiguat) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, praliciguat (IW-1973) / Cyclerion
[VIRTUAL] SAFETY AND EFFICACY OF SOLUBLE GUANYLATE CYCLASE STIMULATORS IN PATIENTS WITH HEART FAILURE (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_960;
Digital databases were queried to identify relevant RCT. The use of sGC stimulators in conjunction with the standard HF therapy might decrease the overall incidence of heart failure-related hospitalization with no overall increase in the net adverse events.
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Clinical: From recent FDA decisions around Vericiguat and Entresto, it is becoming increasingly clear that there are no absolute principles in decision making. As with clinical decision making, regulatory decision-making is as much art as it is science. (Twitter) - Feb 16, 2021
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
New Drug Trials Snapshot available for Verquvo (vericiguat): https://t.co/Yo6w7NYnYQ. View PI: https://t.co/8pNULdEm5G (Twitter) - Feb 9, 2021
- ||| Verquvo (vericiguat) / Bayer, Merck (MSD)
Interview: Our new #interview with @JavedButler1 about #vericiguat is here ! #timetowatch (Twitter) - Feb 5, 2021
- || Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Review, Journal: Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. (Pubmed Central) - Feb 3, 2021
Other strategies to increase tissue cyclic guanosine monophosphate have been attempted, such as PDE-3 or PDE-5 inhibition (with negative or neutral results), NO-independent soluble guanylate cyclase (sGC) activation, or enhancement of sGC sensitivity to endogenous NO. Following the positive results of the phase 3 VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial on the sGC stimulator vericiguat in HFrEF, the main open questions are the efficacy of the sacubitril/valsartan-vericiguat combination in HFrEF and of vericiguat in HFpEF.
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
New P1 trial: A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants (clinicaltrials.gov) - Jan 25, 2021
P1, N=39, Completed, Sponsor: Bayer
- || Verquvo (vericiguat) / Bayer, Merck (MSD)
New P1 trial: A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants (clinicaltrials.gov) - Jan 25, 2021
P1, N=27, Completed, Sponsor: Bayer
- || Review, Journal: Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. (Pubmed Central) - Jan 21, 2021
Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention.
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
I'm interested in the comments because I'm not sure myself - after ARNI/BB/MRA/SGLT2i- where ivabradine, vericiguat, and omecamtiv mecarbil will fit in. (Twitter) - Jan 20, 2021
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Exactly. Those would be, till proven otherwise, eligible for CRT, transplantation or LVAD...And since very ill pts perform worse w/vericiguat, it wouldn't be recommended as an adjunct bridge to advanced support... (Twitter) - Jan 20, 2021
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: @mvaduganathan and @JJheart_doc, there is no way to assess the effect of vericiguat on outcomes in pts treated w/the 4 pillars (which means including SGLT2i) except by means of a new RCT which will probably not be undertaken. I really don't know the role of this class of drug... (Twitter) - Jan 20, 2021
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: Great to see all of the effort of #victoria trial participants come together for #vericiguat approval as an option for #heartfailure patients @CVC_UAlberta @DCRINews @JustinEzekowitz @coconnormd @robmentz (Twitter) - Jan 20, 2021
- ||||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: #VICTORIA enrolled well-treated pts (ACEi/ARB 74%, BB 93%, MRA 70%, ARNI 15%). SGLT2i not reported but low Vericiguat targets overlapping pathways w ARNI, yet similar effects seen in 731 pts on ARNI Will be considered add-on in those w worsening HF despite quadruple Rx (as tol) (Twitter) - Jan 20, 2021
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
New drug approved by @US_FDA for heart failure with reduced ejection fraction: vericiguat, a soluble guanyclate cyclase stimulator @JJheart_doc @mvaduganathan what’s potential role for this drug given that beyond ACE, BB, you now have SGLT2i & Entresto? https://t.co/JMmkYHE8lT (Twitter) - Jan 20, 2021
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
FDA event: $MRK Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) https://t.co/nsYOHl33pl #fdaapproval (Twitter) - Jan 20, 2021
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Industry will try to roll out both vericiguat and omecamtiv for HFrEF. I do not see a major role. Benefit was quite small. (Twitter) - Jan 19, 2021
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: That’s a given but if afib, severe LV dysfunction, rehospitalizations, I’ll use dig over vericiguat or olmecantiv. Patients feel better, have less hospitalization, improved renal function and greater improvement in NYHA class. Caveat: Need to follow the patient and dig level. (Twitter) - Jan 17, 2021
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical: James Januzzi, MD, @JJheart_doc @MGHHeartHealth discusses findings from the recent VICTORIA trial, which found that #vericiguat reduced mortality and hospitalization among recently decompensated heart failure with #HFrEF patients. https://t.co/THRgDqy5s1 (Twitter) - Jan 8, 2021
- | vericiguat (BAY 1021189) / Bayer, Merck (MSD), Adempas (riociguat) / Bayer, praliciguat (IW-1973) / Cyclerion
Journal: cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development. (Pubmed Central) - Jan 6, 2021
This review tries to summarize the contributions to the "9th International cGMP Conference on cGMP Generators, Effectors and Therapeutic Implications" held in Mainz in 2019. Presented data will be discussed and extended also in light of recent landmark findings and ongoing activities in the field of preclinical and clinical cGMP research.
- || Review, Journal: Soluble guanylate cyclase stimulators and their potential use: a patent review. (Pubmed Central) - Jan 5, 2021
Expert Opinion: With the recent advancements reported in the patent literature, sGC stimulators might be differentiated due to tissue selectivity or route of application although exhibiting the same molecular mode of action. The indication space of these compounds is potentially very broad and multiple indications in cardiovascular diseases and beyond are under investigation.
- |||| vericiguat (BAY 1021189) / Bayer, Merck (MSD), Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
2️⃣0️⃣2️⃣0️⃣TRIALS TOP: 📌TICO: Ticagrelor With/out Aspirin in ACS After PCI 📌EMPEROR-Reduced: Empagliflozin in HFrEF 👥 📌VICTORIA: Vericiguat in HFrEF 📌RIVER: Rivaroxaban for Valvular Heart Disease and AF 📂 https://t.co/KYTufWyYKg @secardiologia @DLBHATTMD (Twitter) - Dec 27, 2020
- || vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Clinical, Journal: Vericiguat reduced a composite of CV death or HF hospitalization in patients with HF and reduced LVEF. (Pubmed Central) - Dec 16, 2020
2020;382:1883-93. 32222134.
- ||| vericiguat (BAY 1021189) / Bayer, Merck (MSD)
Got to start by learning to pronounce it! #Vericiguat #heartfailure #VICTORIA @cardiobrief @ProfDFrancis (Twitter) - Dec 8, 2020